Sulprostone: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Intravenous
Cervical dilatation in the 1st trimester

Adult: 500 mcg infusion over 3-6 hr.

Intravenous
Pregnancy termination in the 2nd trimester

Adult: 100 mcg/hr infusion for up to 10 hrs; if necessary, increase infusion rate up to 500 mcg/hr to a max total dose of 1.5 mg. May be repeated once 12-24 hrs later if unsuccessful.

Intravenous
Postpartum haemorrhage

Adult: Initially, 100 mcg/hr via infusion. May increase to 500 mcg/hr if needed to control bleeding, after which reduce to a maintenance dose of 100 mcg/hr. Not to exceed a total dose of 1.5 mg in 24 hr.

Contraindications

Pelvic infection; history of pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease. Smokers or those who have smoked in the last 2 yr.

Special Precautions

Glaucoma or raised intraocular pressure, pre-existing or history of asthma, pre-existing or history of epilepsy, hepatic or renal dysfunction, CV disease.

Adverse Reactions

Bronchoconstriction, nausea, vomiting, diarrhoea, abdominal pain, back pain, rash, flushing,shivering, headache, dizziness, hypotension, hypertension, hypersensitivity reactions, convulsions, EEG changes, local tissue irritation, erythema, pyrexia, raised WBC.
Potentially Fatal: Sudden CV collapse, uterine rupture

Drug Interactions

Concurrent use potentiates effect of oxytocin.

Action

Description: Sulprostone, a synthetic derivative of dinoprostone (prostaglandin E2), is a selective agonist for EP3 receptors.

MIMS Class

Drugs Acting on the Uterus

Disclaimer: This information is independently developed by MIMS based on Sulprostone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com